General Information of the Compound
Compound ID
CP0042568
Compound Name
3-cyclopropyl-1-{3-[5-(morpholin-4-ylmethyl)-1H-1,3-benzodiazol-2-yl]-1H-pyrazol-4-yl}urea
    Show/Hide
Synonyms
AT9283
    Show/Hide
Structure
Formula
C19H23N7O2
Molecular Weight
381.44
Canonical SMILES
O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1
    Show/Hide
InChI
InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)
    Show/Hide
InChIKey
LOLPPWBBNUVNQZ-UHFFFAOYSA-N
CAS
896466-04-9
Physicochemical Property
logP
2.0691
Rotatable Bonds
5
Heavy Atom Count
28
Polar Areas
110.96
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
5
Complexity
28

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 135398495
SID: 47214003
ChEMBL ID
CHEMBL495727
DrugBank ID
DB05169
Clinical Information about the Compound
Drug 1 ( AT9283 )
Drug Name AT9283
Company Astex Therape.
Indication
Solid tumour/cancer
Phase 3
Target(s)
Aurora kinase B (AURKB)
Modulator
Aurora kinase A (AURKA)
Modulator